FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
WALTHAM, Mass., Nov. 16, 2016 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced a public offering of $175,000,000 of its American Depositary Shares ("ADSs"), each representing 13 of its ordinary shares, par value $0.0001 per share. BeiGene is proposing to sell $160,000,000 of its ADSs, and certain selling stockholders are proposing to sell $15,000,000 of BeiGene ADSs. In addition, the underwriters have been granted a 30-day option to purchase up to an additional $26,250,000 of ADSs from BeiGene.
Morgan Stanley, Goldman, Sachs & Co. and Cowen and Company are acting as joint book-running managers.
The offering will be made only by means of a prospectus, copies of which may be obtained for free from the offices of Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, or email: [email protected]; or Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, United States, Attn.: Prospectus Department or by calling +1 (631) 274 2806.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. A registration statement relating to these securities was filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
Investor/Media Contact Lucy Li, Ph.D. +1 781-801-1800 [email protected] [email protected]
